VTRS · 10-Q · 2026Q2 · Full report

Competition and Pricing Pressure

Viatris Inc · 2026-08-06 · Importance 37 · Surprise 42

Viatris operates in a highly competitive pharmaceutical market where additional generic entrants generally reduce affected-product volume and pricing, especially after periods of market exclusivity. Generic entry for Amitiza 24 μg may occur in Japan in December 2026, depending on patent litigation, creating a potential product-specific competitive risk. Government-imposed price reductions and generic tender systems outside the U.S. continue to pressure sales and profitability, with manufacturers often underbidding one another to win priority placement. In Australia, additional competition contributed to lower sales of existing products in the JANZ segment during the first six months of 2026.